Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsSolid TumorsProtocol groupAcute LeukemiasAggressive LymphomasIndolent LymphomasNeuro-OncologyT-Cell and NK-Cell NeoplasmsDiseaseAcute Lymphoblastic LeukaemiaChronic Lymphocytic Leukemia / Small Lymphocytic LymphomaMalignant MeningitisMantle Cell LymphomaNHL, B-Cell Type, Anaplastic Large Cell Lymphoma, ALK-PositiveNHL, B-Cell Type, Burkitt's LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, IndolentNHL, B-Cell Type, Lymphoblastic LymphomaNHL, B-Cell Type, Mediastinal (Thymic) Large B-Cell LymphomaNHL, T-Cell Type, Lymphoblastic LymphomaSubgroupB-ALLHigh riskLow riskPh/BCR-ABL+Ph/BCR-ABL-T-ALLICD10C79.3C82.-C82.7C82.9C83.1C83.3C83.5C83.7C84.6C85.2C91.0-C91.1-MeSHBurkitt LymphomaLymphoma, Mantle-CellMeningeal CarcinomatosisPrecursor B-Cell Lymphoblastic Leukemia-LymphomaSequenceALL,Ph/BCR-ABL+: Hyper-CVAD (CYCL300/VNCR2/DOXO50/DEXA40)/RITU375/IMAT800, ALL/NHL, Ph/BCR-ABL+, C1 (PID2084) -|- C2 (PID2085) -|- C3 (PID2086) -|-C4 (PID2085) -|- C5 (PID2087) -|- C6 (PID2088) -|- C7 (PID2089) -|- C8 (PID2090) -|- Month 1-5 (PID2073) -|- Month 6 (PID2110) -|- Month 7 (PID2113) -|- Month 8-17 (PID2073) -|- Month 18 (PID2110) -|- Month 19 (PID2113) -|- Month 20-24 (PID2073)B-ALL: Hyper-CVAD (CYCL300/VNCR2/DOXO50/DEXA40)/RITU375, B-ALL/NHL, C1 (PID2061) -|- C2 (PID2064) -|- C3 (PID2061) -|- C4 (PID2064) -|- C5 (PID2063) -|- C6 (PID2065) -|- C7 (PID2063) -|- C8 (PID2065) -|- Month 1-5 (PID2072) -|- Month 6 (PID2074) -|- Month 7 (PID2061) -|- Month 8-17 (PID2072) -|- Month 18 (PID2074) -|- Month 19 (PID2061) -|- Month 20-30 (PID2072)DA-EPOCH (ETOP50/PRED120/VNCR0.4/CYCL750/DOXO10)/RITU375, B-NHL, C1-2 (PID658) -|- C3-6 (PID2056)DA-EPOCH-R(R), Burkitt's lymphomaGMALL 08/2013-B-ALL/NHL 2002 Regimen, 18 - 55GMALL 08/2013-B-ALL/NHL 2002 regimen, older than 55, B-ALL onlyGMALL 08/2013-B-ALL/NHL 2002 regimen, older than 55, NHL onlyIXAZ4/RITU1400/DEXA20, Waldenström (PID2025) -|- (PID2026) -|- (PID2027) -|- (PID310)MRC/NCRI LY10, Burkitt's LymphomaR-ICE (RITU375/ETOP100/CRBP635/IFOS3), Burkitt's Lymphoma, C1-2 (PID2223) -|- C3 (PID2224).T-ALL: Hyper-CVAD (CYCL300/VNCR2/DOXO50/DEXA40)/RITU375, ALL/NHL, C1 (PID2061) -|- C2 (PID2064) -|- C3 (PID2061) -|- C4 (PID2064) -|- C4N (PID2083) -|- C5 (PID2063) -|- C5N (PID2083) -|- C6 (PID2065) -|- C7 (PID2063) -|- C8 (PID2065) -|- Month 1-5 (PID2072) -|- Month 6 (PID2083) -|- Month 7 (PID2083) -|- Month 8-17 (PID2072) -|- Month 18 (PID2074) -|- Month 19 (PID2061) -|- Month 20-30 (PID2072)ChemotherapyChemo-substanceCarboplatinCyclophosphamideCytarabineDexamethasoneDoxorubicinEtoposideFolinic acidIfosfamideImatinibMercaptopurineMethotrexateNaCl 0.9%Peg asparaginasePrednisoloneRituximabVincristineVindesineChemo-substanceCarboplatinCyclophosphamideCytarabineDexamethasoneDoxorubicinEtoposideFolinic acidIfosfamideImatinibMercaptopurineMethotrexateNaCl 0.9%Peg asparaginasePrednisoloneRituximabVincristineVindesineChemo-substanceCarboplatinCyclophosphamideCytarabineDexamethasoneDoxorubicinEtoposideFolinic acidIfosfamideImatinibMercaptopurineMethotrexateNaCl 0.9%Peg asparaginasePrednisoloneRituximabVincristineVindesineChemo-substanceCarboplatinCyclophosphamideCytarabineDexamethasoneDoxorubicinEtoposideFolinic acidIfosfamideImatinibMercaptopurineMethotrexateNaCl 0.9%Peg asparaginasePrednisoloneRituximabVincristineVindesineNo. Substances12345678 RadiotherapySupportive therapySupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateSupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateSupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateSupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateNo. Substances12346781014151617Protocol classificationTherapy classificationalternativecurrent standardIntensityDose intensifiedhigh doseStandard doseTherapy indicationFirst lineRelapse therapyTherapy phaseInductionMaintenancePre-phaseReinductionTherapy intentioncurativeRisksAnemia Hb below 8g/dlCardiotoxicityDiarrheaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHypotensionInfectionsMucositisNeuropathyNeutropeniaOral MucositisPyrexiaThrombocytopenia below 50 000/µlTumor Lysis Syndrome only studiesPublicationAuthorDavies ADunleavy KGriffin TCHoelzer DMead GMRausch CRRizzieri DARoschewski MDiseaseBurkitt-Lymphom, ZNS-Befall vor Beginn der TherapieBurkitt-Lymphom bei ErwachsenenBurkitt-Lymphom bei Erwachsenen, ErstlinieErstlinientherapie beim Burkitt-LymphomErstlinientherapie beim primär mediastinalen B-Zell LymphomHochmaligne B-ALL/T-ALL und Burkitt-Lymphom bei Erwachsenen, ErstlinieHochmaligne B-ALL und B-NHL bei Erwachsenen, ErstliniePrimär therapierefraktäres oder rezidiviertes B-NHL oder B-ALL, <21 Jahre, ECOG 0-2OriginCancer Research UK Centre, University of Southampton, UK, SABRINA StudieCenter for Cancer Research, Divison of Cancer Treatment and Diagnosis, National Cancer Institute, BethesdaDivision of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, TexasDuke University Medical Center, Durham, North Carolina, CALGB 9251 trialGerman Multicenter Study Group for Adult Acute Lymphoblastic LeukemiaLymphoid Malignancies Branch, National Cancer Institute, BethesdaMemorial Hospital of South Bend, South BendSouthampton University Hospitals Trust, Southampton, United Kingdom, MRC/NCRI LY10 trialProtocols in Revision 35 protocols foundProtocols under revision.Cyclophosphamide 200 / Prednisolone 60, Pre-phase, Burkitt's lymphoma (PID2214 V1.0)DA-EPOCH-R - Rituximab 375 / Etoposide 50 / Prednisolone 60 / Vincristine 0.4 / Cyclophosphamide 750 / Doxorubicin 10, B-non-Hodgkin Lymphoma, Cycle 1-2 (PID658 V1.2)DA-EPOCH-R - Rituximab 375 / Etoposide 72 / Prednisolone 60 / Vincristine 0.4 / Cyclophosphamide 1080 / Doxorubicin 14.4, B-Non-Hodgkin Lymphoma, Cycle 3-6 (PID2056 V1.2)DA-EPOCH-RR - Rituximab 375 / Etoposide 50 / Prednisolone 60 / Vincristine 0.4 / Cyclophosphamide 750 / Doxorubicin 10, Burkitt lymphoma (PID2222 V1.1)GMALL 08/2013 - B-ALL/NHL 2002 Regimen, 18 - 55, Part A (PID344 V1.2)GMALL 08/2013 - B-ALL/NHL 2002 Regimen, 18 - 55, Part B (PID346 V1.2)GMALL 08/2013 - B-ALL/NHL 2002 Regimen, 18 - 55, Part C (PID347 V1.1)GMALL 08/2013 - B-ALL/NHL 2002 regimen, all ages, Pre-phase (PID345 V1.0)GMALL 08/2013 - B-ALL/NHL 2002 regimen, older than 55, part A, NHL only (PID704 V1.0)GMALL 08/2013 - B-ALL/NHL 2002 regimen, older than 55, part B, NHL only (PID705 V1.0)GMALL 08/2013 - B-ALL/NHL 2002 regimen, Rituximab consolidation (PID784 V1.0)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Doxorubicin 50 / Dexamethasone 40) / Imatinib 600, ALL/NHL, Ph/BCR-ABL+, cycle 5 (PID2087 V1.0)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Ddoxorubicin 50 / Dexamethasone 40) / Imatinib 600, ALL/NHL, Ph/BCR-ABL+, cycle 7 (PID2089 V1.0)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Doxorubicin 50 / Dexamethasone 40) / Rituximab 375 / Imatinib 400, ALL/NHL, Ph/BCR-ABL+, intensification, month 7,19 (PID2113 V1.0)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Doxorubicin 50 / Dexamethasone 40) / Rituximab 375 / Imatinib 600, ALL/NHL, Ph/BCR-ABL+, cycle 3 (PID2086 V1.0)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Doxorubicin 50 / Dexamethasone 40) / Rituximab 375 / Imatinib 800, ALL/NHL, Ph/BCR-ABL+, cycle 1 (PID2084 V1.0)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Doxorubicin 50 / Dexamethasone 40) / Rituximab 375, ALL/NHL, cycle 1,3 (PID2061 V1.0)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Doxorubicin 50 / Dexamethasone 40), ALL/NHL, cycle 5,7 (PID2063 V1.0)Methotrexate 100 / Peg-asparaginase 2000 / Imatinib 400, ALL/NHL, Ph/BCR-ABL+, intensification, month 6,18 (PID2110 V1.1)Methotrexate 100 / Peg-asparaginase 2000, ALL/NHL, intensification, month 6,18 (PID2074 V1.1)Methotrexate 1000 / Cytarabine 3000 / Imatinib 600, ALL/NHL, Ph/BCR-ABL+, cycle 6 (PID2088 V1.1)Methotrexate 1000 / Cytarabine 3000 / Imatinib 600, ALL/NHL, Ph/BCR-ABL+, cycle 8 (PID2090 V1.1)Methotrexate 1000 / Cytarabine 3000, ALL/NHL, cycle 6,8 (PID2065 V1.1)Methotrexate 12, CNS therapy, Burkitt's Lymphoma (PID2231 V1.1)Methotrexate 15 / Cytarabine 30, Burkitt's Lymphoma (PID2240 V1.1)POMP (Mercaptopurine 50 / Vincristine 2 / Methotrexate 20 / Prednisolone 200), ALL/NHL, maintenance, month 1-5,8-17,20-30 (PID2072 V1.0)R-ICE - Rituximab 375 / Etoposide 100 / Carboplatin 5 / Ifosfamide 3, Burkitt's Lymphoma, Cycle 1-2. (PID2223 V1.0)R-ICE - Rituximab 375 / Etoposide 100 / Carboplatin 5 / Ifosfamide 3, Burkitt's Lymphoma, Cycle 3. (PID2224 V1.0)R-IVAC - Cytarabine 2000 / Rituximab 375 / Etoposide 60 / Ifosfamide 1.5, Burkitt's lymphoma (PID2212 V1.0)R-modified CODOX-M - Rituximab 375 / Cyclophosphamide (800/200) / Vincristine 2 / Doxorubicin 40 / Methotrexate 3000, Burkitt lymphoma (PID2211 V1.2)Rituximab 1400, single dose subcutaneous (PID310 V2.0)Rituximab 375 / Methotrexate 1000 / Cytarabine 3000 / Imatinib 600, ALL/NHL, Ph/BCR-ABL+, cycle 2,4 (PID2085 V1.1)Rituximab 375 / Methotrexate 1000 / Cytarabine 3000, ALL/NHL, cycle 2,4 (PID2064 V1.1)Rituximab 375, Burkitt's lymphoma (PID2218 V1.0)Vincristine 2 / Prednisolone 200 / Imatinib 400, ALL/NHL, maintenance, Ph/BCR-ABL+ (PID2073 V1.0)
